Wajeh Qunibi

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. pmc A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease
    Wajeh Qunibi
    Department of Medicine, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    BMC Nephrol 12:9. 2011
  2. pmc A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Science Centre and Texas Diabetes Institute, San Antonio, TX, USA
    Nephrol Dial Transplant 26:1599-607. 2011
  3. doi request reprint The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review
    Wajeh Y Qunibi
    Department of Medicine, Division of Nephrology, University of Texas Health Sciences Center, San Antonio 78229 3900, USA
    Arzneimittelforschung 60:399-412. 2010
  4. ncbi request reprint Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?
    W Y Qunibi
    Nephrology Division, Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Clin Nephrol 73:276-85. 2010
  5. doi request reprint A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study
    Wajeh Qunibi
    Department of Medicine, Division of Nephrology, University of Texas Health Sciences Center, San Antonio, TX 78229 3900, USA
    Am J Kidney Dis 51:952-65. 2008
  6. ncbi request reprint Cardiovascular calcification in nondialyzed patients with chronic kidney disease
    Wajeh Y Qunibi
    Nephrology Division, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Semin Dial 20:134-8. 2007
  7. ncbi request reprint The CARE study and cardiovascular calcification
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center, San Antonio 78229 3900, USA
    Manag Care 15:1-5. 2006
  8. ncbi request reprint Reducing the burden of cardiovascular calcification in patients with chronic kidney disease
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Am Soc Nephrol 16:S95-102. 2005
  9. ncbi request reprint Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Kidney Int 68:271-7. 2005
  10. ncbi request reprint Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients
    Charles R Nolan
    University of Texas Health Sciences Center, San Antonio, Texas, USA
    Curr Opin Nephrol Hypertens 12:373-9. 2003

Detail Information

Publications14

  1. pmc A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease
    Wajeh Qunibi
    Department of Medicine, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    BMC Nephrol 12:9. 2011
    ..This trial was conducted to examine the efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD...
  2. pmc A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Science Centre and Texas Diabetes Institute, San Antonio, TX, USA
    Nephrol Dial Transplant 26:1599-607. 2011
    ..Current intravenous iron agents cannot be administered in a single high dose because of adverse effects. Ferric carboxymaltose, a non-dextran parenteral iron preparation, can be rapidly administered in high doses...
  3. doi request reprint The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review
    Wajeh Y Qunibi
    Department of Medicine, Division of Nephrology, University of Texas Health Sciences Center, San Antonio 78229 3900, USA
    Arzneimittelforschung 60:399-412. 2010
    ..v. iron preparations. This agent has been shown to be effective and well tolerated in a number of randomized controlled trials in a variety of chronic conditions...
  4. ncbi request reprint Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?
    W Y Qunibi
    Nephrology Division, Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Clin Nephrol 73:276-85. 2010
    ..It is not clear whether the K/DOQI recommended doses of ergocalciferol are adequate for correction of VDDI and hyperparathyroidism...
  5. doi request reprint A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study
    Wajeh Qunibi
    Department of Medicine, Division of Nephrology, University of Texas Health Sciences Center, San Antonio, TX 78229 3900, USA
    Am J Kidney Dis 51:952-65. 2008
    ....
  6. ncbi request reprint Cardiovascular calcification in nondialyzed patients with chronic kidney disease
    Wajeh Y Qunibi
    Nephrology Division, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Semin Dial 20:134-8. 2007
    ..Finally, I will review the protective role of inhibitors of calcification in CKD...
  7. ncbi request reprint The CARE study and cardiovascular calcification
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center, San Antonio 78229 3900, USA
    Manag Care 15:1-5. 2006
    ....
  8. ncbi request reprint Reducing the burden of cardiovascular calcification in patients with chronic kidney disease
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Am Soc Nephrol 16:S95-102. 2005
    ..Moreover, the review is intended to stimulate more research in this area because the efficacy of these interventions has not been examined in controlled clinical trials...
  9. ncbi request reprint Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Kidney Int 68:271-7. 2005
    ..However, the prevalence and severity of CVC is less well documented in patients with chronic kidney disease (CKD) not yet on dialysis...
  10. ncbi request reprint Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients
    Charles R Nolan
    University of Texas Health Sciences Center, San Antonio, Texas, USA
    Curr Opin Nephrol Hypertens 12:373-9. 2003
    ..In this regard, sevelamer hydrochloride has been recommended as an alternative phosphate binder. In this review, we will examine these issues and provide rational guidelines for the use of calcium-based phosphate binders...
  11. ncbi request reprint Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)
    Wajeh Y Qunibi
    Department of Medicine, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas 78229 3900, USA
    Kidney Int 65:1914-26. 2004
    ..Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients...
  12. ncbi request reprint How should hyperphosphatemia be managed in dialysis patients?
    Geoffrey Block
    Denver Nephrology, Denver, Colorado
    Semin Dial 15:315-28. 2002
  13. ncbi request reprint Economic impact of sevelamer in patients with ESRD
    Wajeh Y Qunibi
    Kidney Int 67:1636-7. 2005
  14. ncbi request reprint Kaposi's sarcoma in Sudanese renal transplant recipients: a report from a single center
    Abdalla I Sabeel
    Department of Medicine, Section of Nephrology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    J Nephrol 16:412-6. 2003
    ..The incidence of Kaposi's sarcoma (KS) in Sudanese renal transplant recipients is not known...